By combining advanced cellular reprogramming with AI-driven protein design, the company aims to reverse biological ageing and tackle multiple diseases at once.
Details at;
3 Likes
Very good! Between Sam Altman’s Retro Bioscience and Demis Hassabis’ Isomorphic labs hopefully we are going to see some results eventually.
My concern is that the hype tends to overwhelm reality.
By the way, Isomorphic is been currently used by some pharmaceutical giants to drastically cut the time required to select candidate molecules.
The more the participants in this race, the higher the likelihood of success. Hopefully.
https://www.perplexity.ai/search/11eea5c6-62e0-4279-8604-1c2a62df8f5a
4 Likes
I think you are mistaken, I have never heard of Retro doing anything like plasmapheresis. They started with $180 million from sam altman, they have no need for short term revenue.
